



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Xu Zhang

✉ zhangxu5920@outlook.com

XiaoHua Wu

✉ wu.xh@fudan.edu.cn

†These authors have contributed equally to this work

RECEIVED 24 May 2024

ACCEPTED 18 June 2024

PUBLISHED 02 July 2024

CITATION

Li J, Zhang X, Yang L, Zhu Y, Gao R, Zhang T, Chen X, Fu J, He G, Shi H, Peng S and Wu X (2024) Corrigendum: Targeted proteomics-determined multi-biomarker profiles developed classifier for prognosis and immunotherapy responses of advanced cervical cancer.
Front. Immunol. 15:1437676.
doi: 10.3389/fimmu.2024.1437676

COPYRIGHT

© 2024 Li, Zhang, Yang, Zhu, Gao, Zhang, Chen, Fu, He, Shi, Peng and Wu. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Targeted proteomics-determined multi-biomarker profiles developed classifier for prognosis and immunotherapy responses of advanced cervical cancer

Jin Li^{1,2†}, Xu Zhang^{3,4*†}, Liuke Yang⁵, Youwei Zhu⁶, Rongrong Gao⁷, Tiancheng Zhang^{3,4}, Xuwen Chen⁸, Jun Fu⁹, Gaoyang He⁹, Huijuan Shi^{3,4}, Shenjie Peng¹⁰ and XiaoHua Wu^{1,2*}

¹Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China, ²Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, ³NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai, China, ⁴Shanghai-MOST Key Laboratory of Health and Disease Genomics, NHC Key Lab of Reproduction Regulation, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai, China, ⁵College of plant protection, Nanjing Agricultural University, Nanjing, China, ⁶Clinical Center of Bio-Therapy at Zhongshan Hospital & Institutes of Biomedical Sciences, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China, ⁷Clinical Center for Biotherapy at Zhongshan Hospital, Fudan University, Shanghai, China, ⁸Shanghai Kelin Clinical Bioinformatics Institute, Shanghai, China, ⁹LC-Bio Technology Co., Ltd, Hangzhou, China, ¹⁰Fudan University, Shanghai, China

KEYWORDS

cervical cancer, biomarker, proteomics, prognosis, immunotherapy response

A Corrigendum on

Targeted proteomics-determined multi-biomarker profiles developed classifier for prognosis and immunotherapy responses of advanced cervical cancer

by Zhang X, Li J, Yang L, Zhu Y, Gao R, Zhang T, Chen X, Fu J, He G, Shi H, Peng S and Wu X (2024). *Front. Immunol.* 15:1391524. doi: 10.3389/fimmu.2024.1391524

In the published article, there was an error in affiliation 1, 2, 3, 4. Instead of “¹NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai, China

²Shanghai-MOST Key Laboratory of Health and Disease Genomics, NHC Key Lab of Reproduction Regulation, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai, China

³Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China

⁴Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China”, it should be “¹Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China

²Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

³NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai, China

⁴Shanghai-MOST Key Laboratory of Health and Disease Genomics, NHC Key Lab of Reproduction Regulation, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 20037, China”.

In the published article, there was an error in the author list, and the first two authors appeared in the wrong order. The corrected author list appears below.

Jin Li^{1,2,†}, Xu Zhang^{3,4,†,*}, Liuke Yang⁵, Youwei Zhu⁶, Rongrong Gao⁷, Tiancheng Zhang^{3,4}, Xuwen Chen⁸, Jun Fu⁹, Gaoyang He⁹, Huijuan Shi^{3,4}, Shenjie Peng¹⁰, XiaoHua Wu^{1,2,*}.

In the published article, there was an error of incorrect representation of the name of the ethics committee and errors in the choice between work email and personal email of co-correspondence author.

A correction has been made to Ethics statement and correspondence section. This sentence previously stated:

“The studies involving humans were approved by the ethics committee of Fudan University Cancer Hospital Shanghai, China.”

XiaoHua Wu xhwu2313@163.com

The corrected sentence appears below:

“The studies involving human participants were reviewed and approved by Ethics Committee of Fudan University Shanghai Cancer Center (approval number: 050432-4-1805C).”

XiaoHua Wu wu.xh@fudan.edu.cn

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.